R&D Failures Mean Lean Future, Falling Stocks for Lilly
Wall Street analysts do not have high hopes for Eli Lilly's revenue until 2020.
A string of R&D failures has left Lilly with nothing that even remotely approaches the $5 billion in annual sales of Cymbalta, Lilly’s best-selling drug, which will see its U.S. patents expire in December.
Experts predict seven lean years for the drugmaker, in which its executives will have to focus on producing profits more through reducing expenses than growing sales. Read the full analysis.